Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer

Authors

  • Anri Inaki Department of Nuclear Medicine, Kanazawa University Hospital
  • Daiki Kayano Daiki Kayano: Department of Nuclear Medicine, Kanazawa University Hospital
  • Junichi Taki Department of Nuclear Medicine, Kanazawa University Hospital
  • Seigo Kinuya Department of Nuclear Medicine, Kanazawa University Hospital
Abstract:

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual lesions by their serum thymoglobulin levels or their scintigrams at the first therapies, they underwent the second 131I therapies without diagnostic scintigraphy after the first therapies. After confirming the sufficient elevation of TSH concentration, thyroid hormone replacement was resumed one day before 131I administration (3.7-7.4GBq).  The ablation rate of thyroid remnant at the first 131I therapy was evaluated by comparing 131I post-therapeutic images of the two treatments. Results: Three patients were administrated thyroid hormone after 131I therapy because of insufficient TSH concentration under thyroid hormone withdrawal. In the remaining 26 patients, 41 thyroid remnant accumulations were detected in all 26 patients at the first 131I therapy. Based on the second 131I post-therapeutic images, successful ablation was confirmed in 24 of 26 patients (92.3%) and 38 of 41 sites (92.7%), which was comparable with historically reported ablation rates. Conclusion: Thyroid hormone replacement one day before 131I therapy could provide a sufficiently high ablation rate in patients with DTC.    

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

thyroid hormone replacement one day before 131i therapy in patients with well-differentiated thyroid cancer

objective: the current study aimed to determine the efficacy of radioiodine-131 (131i) ablation therapy with thyroid hormone replacement one day before 131i administration in patients with well-differentiated thyroid cancer (dtc). methods: this retrospective study included 29 patients who underwent 131i therapies twice for dtc during 6-12 months.  since all the patients obviously had residual l...

full text

Factors affecting discharge time of well differentiated thyroid cancer patients receiving 131I therapy: Five years’ experience

Introduction:The post-surgical management of patients with differentiated thyroid cancer include ablation of remnant local and distant metastatic tissues with 131I therapy, which accentuates isolation of the patient in order to avoid unnecessary radiation exposure to the care givers, general public and the environment. The duration of isolation is subject to the redu...

full text

Radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [Persian]

Salivary gland involvement is one of the radioiodine therapy complications. Salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. Methods: Salivary gland scintigraphy was performed with Tc-99m Pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. Ejection Fraction (EF) of parotid and submandibula...

full text

Thyroid Hormone Replacement in Patients Following Thyroidectomy for Thyroid Cancer

Thyroid hormone replacement therapy in patients following thyroidectomy for thyroid cancer, although a potentially straightforward clinical problem, can present the clinician and patient with a variety of challenges. Most often the problems are related to the dose and preparation of thyroid hormone (TH) to use. Some patients feel less well following thyroidectomy and/or radioiodine ablation tha...

full text

Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.

Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before 131I administration for treatment. The objective of this study was to compare the absorbed dose to the critical organs and tumors determined by 124I PET/CT-based dosimetry for 131I therap...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 1  issue 1

pages  20- 26

publication date 2013-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023